Vir Biotechnology (VIR) News Today $5.24 +0.02 (+0.38%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$5.28 +0.04 (+0.86%) As of 06/16/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have given a buy ratinJune 12, 2025 | marketbeat.comBank of America Corp DE Has $1.42 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)Bank of America Corp DE decreased its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 42.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 193,650 shares of the company's stock after selling 142,943 shares during the period. Bank of AmeJune 6, 2025 | marketbeat.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 3,200 Shares of StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Janet Napolitano sold 3,200 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $5.05, for a total value of $16,160.00. Following the completion of the transaction, the director now owns 16,416 shares of the company's stock, valued at $82,900.80. This represents a 16.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.June 3, 2025 | marketbeat.comJanet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJune 3, 2025 | insidertrades.comNuveen Asset Management LLC Has $2.64 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Nuveen Asset Management LLC lessened its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 31.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 359,572 shares of tJune 3, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.6% - Here's What HappenedVir Biotechnology (NASDAQ:VIR) Shares Down 7.6% - Should You Sell?May 31, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading 6.6% Higher - What's Next?Vir Biotechnology (NASDAQ:VIR) Shares Up 6.6% - Time to Buy?May 30, 2025 | marketbeat.comVir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and OncologyMay 29, 2025 | investing.comVir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025May 28, 2025 | businesswire.comVoloridge Investment Management LLC Lowers Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Voloridge Investment Management LLC lessened its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 21.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 769,725 shares of the company's stock after seMay 28, 2025 | marketbeat.comWoodline Partners LP Makes New $991,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)Woodline Partners LP bought a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 135,036 shares of the company's stock, valued at approximaMay 28, 2025 | marketbeat.comMillennium Management LLC Has $12.59 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Millennium Management LLC increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 55.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,715,083 shares of the company's stock after purchasing an addiMay 26, 2025 | marketbeat.comVir Biotechnology's (VIR) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $14.00 target price on shares of Vir Biotechnology in a research report on Thursday.May 24, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of VIR Q2 EarningsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of Vir Biotechnology in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now anticipates that the comMay 24, 2025 | marketbeat.comVir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)May 22, 2025 | benzinga.comPoint72 Asset Management L.P. Raises Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Point72 Asset Management L.P. lifted its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 16,169.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 848,454 shares of the company's stock after buying an additional 843,May 22, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. lowered its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 46.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 502,000 shares of the company's stock after selling 428,655 shares duMay 21, 2025 | marketbeat.comStonepine Capital Management LLC Takes Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Stonepine Capital Management LLC acquired a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 164,106 shares of the company's stockMay 20, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from BrokeragesVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued aMay 20, 2025 | marketbeat.comSphera Funds Management LTD. Boosts Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Sphera Funds Management LTD. boosted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 523.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 581,829 shares of the company's stoMay 18, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Algert Global LLCAlgert Global LLC lessened its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 90.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,802 shares of the company's stock after selling 193,663 shares during the qMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Orbimed Advisors LLC reduced its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,218,617 shares of the company's stock after selling 354,383 sharMay 15, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Hudson Bay Capital Management LPHudson Bay Capital Management LP increased its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 60.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 849,873 shares of the compaMay 15, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at Needham & Company LLCNeedham & Company LLC lowered their price objective on shares of Vir Biotechnology from $19.00 to $14.00 and set a "buy" rating for the company in a research report on Monday.May 14, 2025 | marketbeat.comVir’s hepatitis B combo falls short in Phase II trialMay 12, 2025 | msn.comVir Biotechnology to Participate in Bank of America Securities 2025 Healthcare ConferenceMay 12, 2025 | businesswire.comBridgeway Capital Management LLC Sells 66,538 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Bridgeway Capital Management LLC lessened its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 20.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 263,243 shares of the company's stock after selling 66,538May 12, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 58.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,915,465 shares of the company's stock after purchasing an additional 703,360May 11, 2025 | marketbeat.comVir Biotechnology First Quarter 2025 Earnings: Revenues DisappointMay 10, 2025 | finance.yahoo.comDAFNA Capital Management LLC Invests $734,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)DAFNA Capital Management LLC purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 100,000 shares of the company's stock, valMay 10, 2025 | marketbeat.comQ1 2025 Vir Biotechnology Inc Earnings CallMay 10, 2025 | finance.yahoo.comVir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH StudyMay 9, 2025 | businesswire.comVir Biotechnology’s Earnings Call: Mixed Sentiment Amid ProgressMay 8, 2025 | tipranks.comVir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV TreatmentMay 8, 2025 | seekingalpha.comVir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virusMay 8, 2025 | msn.comVir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...May 8, 2025 | uk.finance.yahoo.comVir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | businesswire.com1,084,539 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Baker BROS. Advisors LPBaker BROS. Advisors LP bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,084,539 shares of the company's stock, valued at approximately $7,961,000. Baker BROS.May 6, 2025 | marketbeat.comWells Fargo & Company MN Has $387,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)Wells Fargo & Company MN trimmed its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 79.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 52,661 shares of the company's stock after selling 199,096 sharesMay 6, 2025 | marketbeat.comBarclays PLC Has $1.62 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Barclays PLC reduced its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 59.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 221,178 shares of the company's stock after selling 329,008 shares during the quarter. Barclays PLC owMay 5, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Invests $1.48 Million in Vir Biotechnology, Inc. (NASDAQ:VIR)Susquehanna Fundamental Investments LLC purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 201,185 sharesMay 3, 2025 | marketbeat.comTower Research Capital LLC TRC Has $451,000 Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Tower Research Capital LLC TRC increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 308.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,391 shares of the company's stock after puMay 2, 2025 | marketbeat.comVir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025April 30, 2025 | businesswire.comVir Biotechnology (VIR) to Release Earnings on ThursdayVir Biotechnology (NASDAQ:VIR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-vir-biotechnology-inc-stock/)April 26, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the companyApril 25, 2025 | marketbeat.comVir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025April 24, 2025 | businesswire.comVir Biotechnology (NASDAQ:VIR) Shares Up 5.5% - Here's What HappenedVir Biotechnology (NASDAQ:VIR) Stock Price Up 5.5% - Should You Buy?April 23, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Up 28.3% in MarchVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 10,110,000 shares, an increase of 28.3% from the March 15th total of 7,880,000 shares. Currently, 11.6% of the company's shares are sold short. Based on an average trading volume of 2,080,000 shares, the days-to-cover ratio is presently 4.9 days.April 21, 2025 | marketbeat.comWalleye Capital LLC Increases Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Walleye Capital LLC increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 2,119.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 434,460 shares of the company's stock after buying anApril 20, 2025 | marketbeat.com Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼1.450.90▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼25▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News MOR News IMVT News HCM News AAPG News OGN News APLS News XENE News AMRX News MIRM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
